0001437749-21-006752.txt : 20210322 0001437749-21-006752.hdr.sgml : 20210322 20210322161042 ACCESSION NUMBER: 0001437749-21-006752 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20210322 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210322 DATE AS OF CHANGE: 20210322 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOLIFE SOLUTIONS INC CENTRAL INDEX KEY: 0000834365 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 943076866 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36362 FILM NUMBER: 21761404 BUSINESS ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 BUSINESS PHONE: 4254011400 MAIL ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 FORMER COMPANY: FORMER CONFORMED NAME: BIOLIFE SOLUTION INC DATE OF NAME CHANGE: 20030113 FORMER COMPANY: FORMER CONFORMED NAME: CRYOMEDICAL SCIENCES INC DATE OF NAME CHANGE: 19920703 8-K 1 bioli20210322_8k.htm FORM 8-K bioli20210322_8k.htm
false 0000834365 0000834365 2021-03-22 2021-03-22
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): March 22, 2021
 
BIOLIFE SOLUTIONS, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
  
001-36362
  
94-3076866
(State or other jurisdiction of
incorporation)
  
(Commission File Number)
  
(IRS Employer Identification No.)
3303 Monte Villa Parkway,
Bothell, WA 98021
(Address of principal executive offices) (Zip Code)
 
Registrant’s telephone number, including area code: (425) 402-1400
 
N/A
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
         ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
         ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
         ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
         ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading symbol
Name of exchange on which registered
BioLife Solutions, Inc. Common Shares
BLFS
NASDAQ Capital Market
 
 
 
 
Item 2.02         Results of Operations and Financial Condition.
 
On March 22, 2021, BioLife Solutions, Inc. (the “Company”) issued a press release announcing the financial results and operational highlights for the fourth quarter and full year ended December 31, 2020. A copy of the press release is furnished as Exhibit 99.1 to this current report on Form 8-K.
 
On March 22, 2021, the Company announced it had entered into a definitive agreement and plan of merger (the “Merger Agreement”), pursuant to which, subject to the terms and conditions set forth therein, a newly formed Delaware subsidiary of the Company will merge with and into Global Cooling, Inc. (“GCI”), a Delaware corporation. GCI, a manufacturer of ultra-low temperature mechanical freezers, which will continue as the surviving corporation and a wholly-owned subsidiary of the Company. The announcement included certain financial information about the Company for the quarter and year ended December 31, 2020 and certain preliminary unaudited 2020 financial information about GCI. In addition, the Company provided certain joint projections for the year 2021 and 2022.
 
A copy of the press release issued by the Company announcing the execution of the Merger Agreement is included as Exhibit 99.2 to this Current Report on Form 8-K.
 
 
Item 9.01         Financial Statements and Exhibits.
 
(d) Exhibits
 
Exhibit No.
  
Description
99.1
  
99.2
  
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 
 
 
SIGNATURE
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
BioLife Solutions, Inc.
 
  
Date: March 22, 2021
By:
/s/ Roderick de Greef
  
   
Name: Roderick de Greef
Title: Chief Financial Officer and Chief
Operating Officer
  
 
 
 EX-99.1 2 ex_235925.htm EXHIBIT 99.1 ex_235925.htm

Exhibit 99.1

 

biolife.jpg
 

BioLife Solutions Announces Fourth Quarter and Full Year 2020 Financial Results

 

Q4 total revenue of $14.7 million increased 78%, full year total revenue of $48.1 million increased 76%

 

Introduces guidance for 2021 total revenue of $101 million to $110 million, up 110% to 129% over 2020

 

Conference call begins at 4:30 p.m. Eastern time today

 

BOTHELL, Wash. (March 22, 2021) – BioLife Solutions, Inc. (NASDAQ: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced financial results for the fourth quarter and year ended December 31, 2020.

 

Mike Rice, BioLife President & CEO, commented, “Despite the COVID-19 pandemic, the BioLife team delivered another quarter and year of stellar operational and financial results. We gained more than 200 new direct customers across our bioproduction tools and services portfolio and more than 3,500 new indirect media customers that sourced our products from distributors. We also drove further adoption of all our other portfolio offerings within the cell and gene therapy space.

 

“With our acquisition of Stirling Ultracold announced earlier today, we expect to surpass our goal of $100 million in total revenue this year and expect to reach $250 million in total revenue in the next three to four years.”

 

Fourth Quarter 2020 Highlights

 

 

●

Acquired SciSafe Holdings, Inc., which became a wholly owned subsidiary of the Company on October 1, 2020. Management now estimates that SciSafe will contribute revenue of at least $12 million in 2021, up from previous expectations of $9 million.

 

 

●

Biopreservation media revenue was $8.2 million, an increase of 58% compared with the same period in 2019.

 

 

●

Gained 213 new direct customers including 63 using biopreservation media, 29 using ThawSTAR® systems, 43 using evo® cold chain management services, 73 using CBS freezers and accessories, and 5 using biologic storage services.

 

 

●

Processed 75 new U.S. FDA Drug Master File cross-reference requests, indicating the planned use of CryoStor® or HypoThermosol® in pending cell and gene therapy clinical trials. To date, the Company’s biopreservation media products have been incorporated into more than 450 customer clinical applications.

 

Page 1 of 11
 

 

Financial Highlights for the Fourth Quarter and Year Ended December 31, 2020

 

BioLife Solutions is presenting various financial metrics under U.S. Generally Accepted Accounting Principles (GAAP) and as adjusted (non-GAAP) to reflect acquisition-related activity. A reconciliation of GAAP to non-GAAP metrics appears at the end of this news release.

 

REVENUE

 

 

●

Total revenue for the fourth quarter of 2020 increased 78% to $14.7 million compared with $8.3 million for the fourth quarter of 2019.
 

o

Biopreservation media revenue was $8.2 million, up 58% over the fourth quarter of 2019
 

o

Automated thawing product revenue was $662,000
 

o

evo cold chain management rental revenue was $469,000
 

o

CBS freezer and related accessories revenue was $3.6 million
 

o

SciSafe biological and pharmaceutical storage revenue was $1.8 million

 

 

●

Total revenue for the year ended December 31, 2020 increased 76% to $48.1 million compared with $27.4 million for the year ended December 31, 2019.
 

o

Biopreservation media revenue was $31.0 million, up 32% over 2019
 

o

Automated thawing product revenue was $1.7 million
 

o

evo cold chain management rental revenue was $1.8 million
 

o

CBS freezer and related accessories revenue was $11.8 million
 

o

SciSafe biological and pharmaceutical storage revenue was $1.8 million

 

GROSS MARGIN

 

 

●

Gross margin (GAAP) for the fourth quarter of 2020 was 50% compared with 57% for the fourth quarter of 2019, while adjusted gross margin (non-GAAP) for the fourth quarter of 2020 was 54% compared with 65% for the fourth quarter of 2019.

 

 

●

Gross margin (GAAP) for the year ended December 31, 2020 was 52% compared with 65% for the same period in 2019, while adjusted gross margin (non-GAAP) for the year ended December 31, 2020 was 58% compared with 69% for the year ended December 31, 2019.

 

 

●

The decline in 2020 fourth quarter and full year gross margin was due to products acquired in the second half of 2019. For the fourth quarter of 2020 the decline also reflected lower margin on biopreservation media products and higher manufacturing overhead.

 

Page 2 of 11
 

 

OPERATING EXPENSE

 

 

●

Operating expense (GAAP) for the fourth quarter of 2020 was $19.5 million compared with $9.1 million for the fourth quarter of 2019, while adjusted operating expense (non-GAAP) for the fourth quarter of 2020 was $8.2 million compared with $4.9 million for the fourth quarter 2019.

 

 

●

Operating expense (GAAP) for the year ended December 31, 2020 was $53.7 million compared with $27.6 million for the same period in 2019, while adjusted operating expense (non-GAAP) for the year ended December 31, 2020 was $27.6 million compared with $16.8 million for the year ended December 31, 2019.

 

 

●

The increase in operating expense in the fourth quarter and year ended December 31, 2020 was primarily due to acquisitions completed in the second half of 2019 and the fourth quarter of 2020, and personnel costs including stock compensation.

 

OPERATING INCOME/(LOSS)

 

 

●

Operating loss (GAAP) for the fourth quarter of 2020 was $4.7 million compared with operating loss of $763,000 for the fourth quarter of 2019, while adjusted operating loss (non-GAAP) for the fourth quarter of 2020 was $255,000 compared with adjusted operating income of $437,000 for the fourth quarter of 2019.

 

 

●

Operating loss (GAAP) for the year ended December 31, 2020 was $5.6 million compared with operating loss of $220,000 for the year ended December 31, 2019, while adjusted operating income (non-GAAP) for the year ended December 31, 2020 was $293,000 compared with adjusted operating income of $2.1 million for the year ended December 31, 2019.

 

NET INCOME/(LOSS)

 

 

●

Net loss (GAAP) for the fourth quarter of 2020 was $2.1 million compared with net income of $3.0 million for the fourth quarter of 2019. Net loss (GAAP) for the fourth quarter of 2020 included operating expense of $3.1 million related to the change in fair value of contingent consideration, other expense of $866,000 related to the change in fair value of warrants, other income of $209,000 related to change in fair value of investments and income tax benefit of $3.3 million. Net income for the fourth quarter of 2019 included other income of $2.1 million related to the change in fair value of warrants and income tax benefit of $1.5 million. Adjusted net loss (non-GAAP) for the fourth quarter of 2020 was $256,000 compared with adjusted net income of $527,000 for the fourth quarter of 2019.

 

 

●

Net income (GAAP) for the year ended December 31, 2020 was $2.7 million compared with a net loss of $1.7 million for the same period in 2019. Net income (GAAP) for the year ended December 31, 2020 included other income of $3.6 million related to the change in fair value of warrants, other expense of $1.6 million related to the change in fair value of contingent consideration, other income of $1.3 million related to the change in fair value of investments and income tax benefit of $3.3 million. Net loss for the year ended December 31, 2019 included other expense of $12.8 million related to the change in fair value of outstanding warrants, other income of $10.1 million related to the gain on acquisition of SAVSU and income tax benefit of $1.5 million. Adjusted net income (non-GAAP) for the year ended December 31, 2020 was $351,000 compared with adjusted net income of $2.6 million for the year ended December 31, 2019.

 

Page 3 of 11
 

 

EARNINGS/(LOSS) PER SHARE

 

 

●

Loss per share (GAAP) for the fourth quarter of 2020 was $0.06 compared with earnings per diluted share of $0.03 for the fourth quarter of 2019. Adjusted loss per share (non-GAAP) for the fourth quarter of 2020 was $0.01 compared with adjusted earnings per diluted share of $0.02 for the fourth quarter of 2019.

 

 

●

Loss per share (GAAP) for the year ended December 31, 2020 was $0.03 compared with loss per share of $0.09 for the year ended December 31, 2019. Adjusted earnings per diluted share (non-GAAP) for the year ended December 31, 2020 was $0.01 compared with $0.13 for the year ended December 31, 2019.

 

EBITDA

 

 

●

EBITDA, a non-GAAP measure, for the fourth quarter of 2020 was negative $3.9 million compared with $2.3 million for the fourth quarter of 2019, while adjusted EBITDA for the fourth quarter of 2020 was $2.5 million compared with $1.7 million for the fourth quarter of 2019.

 

 

●

EBITDA for the year ended December 31, 2020 was $4.4 million compared with negative $1.9 million the year ended December 31, 2019, while adjusted EBITDA for the year ended December 31, 2020 was $8.3 million compared with $5.9 million for the year ended December 31, 2019.

 

CASH

 

 

●

Cash, cash equivalents, and restricted cash as of December 31, 2020 were $90.5 million compared with $6.4 million as of December 31, 2019. The increase reflects a $20 million common share purchase agreement with Casdin Capital LLC during the second quarter of 2020, an $86 million capital raise in the third quarter of 2020 and $15.0 million deployed in the purchase of SciSafe in the fourth quarter of 2020.

 

Roderick de Greef, BioLife’s Chief Financial Officer and Chief Operating Officer, remarked, “Despite a negative impact on capital equipment product revenue due to COVID-19 restrictions on in-person customer meetings throughout most of 2020, our media business grew consistently, increasing 32% compared with 2019 and contributing to very strong overall revenue growth. With our recently announced acquisition of Stirling Ultracold, we now have an even broader product offering to expand our addressable market and better serve our growing customer base.”

 

Page 4 of 11
 

 

2021 Total Revenue Guidance

 

Our 2021 revenue guidance is based on current expectations for our existing business, and includes anticipated contributions from our acquisition of Stirling Ultracold, which is expected to close on or before May 1, 2021.

 

Total revenue for 2021 is expected to be in the range of $101 million to $110 million, reflecting year-over-year revenue growth of 110% to 129%. Our total revenue expectation for 2021 includes the following:

 

 

●

Expected contribution of $35 million to $37 million from the Stirling Ultracold product line.

 

 

●

For 2021, we will report revenue in three product categories: Media; Freezer and Thaw Systems including our freezer systems and ThawSTAR product lines; and Services including our evo cold chain and biostorage services.

 

 

●

Media revenue is expected to be between $38 million and $40 million, reflecting growth of 23% to 29% over 2020 and accounting for approximately 37% of total revenue.

 

 

●

Freezer and thaw systems revenue is expected to be between $50 million and $54 million, accounting for approximately 50% of total revenue.

 

 

●

Services revenue is expected to be between $13 million and $16 million, accounting for approximately 13% of total revenue.

 

Conference Call & Webcast

 

Management will discuss the Company's financial results and provide a general business update including a discussion of the Stirling Ultracold acquisition on a conference call and live webcast today at 4:30 p.m. ET (1:30 p.m. PT).

 

To access the webcast, log onto the Investor Relations page of the BioLife Solutions website at http://www.biolifesolutions.com/earnings. Alternatively, you may access the live conference call by dialing (844) 825-0512 or (315) 625-6880 with the following Conference ID: 7158827. A webcast replay will be available approximately two hours after the call and will be archived on http://www.biolifesolutions.com/ for 90 days.

 

Page 5 of 11
 

 

About BioLife Solutions

 

BioLife Solutions is a leading supplier of cell and gene therapy bioproduction products and services. Our portfolio includes our proprietary CryoStor® freeze media and HypoThermosol® shipping and storage media, ThawSTAR® family of automated, water-free thawing products, evo® cold chain management system, Custom Biogenic Systems® high-capacity storage freezers, and SciSafe biologic materials storage. For more information, please visit www.biolifesolutions.com, www.savsu.com, www.custombiogenics.com, and www.scisafe.com, and follow BioLife on Twitter.

 

Cautions Regarding Forward Looking Statements

 

Except for historical information contained herein, this presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements concerning the expected financial performance of the company following the completion of its 2019 and 2020 acquisitions and giving effect to the COVID-19 pandemic, the company's ability to implement its business strategy and anticipated business and operations, in particular following the closing of its acquisition of Global Cooling, the expected synergies between the company and Global Cooling, the company’s ability to realize all or any of the anticipated benefits associated with the acquisition of Global Cooling, the company's ability to implement its business strategy and anticipated business and operations, including following the acquisition of Global Cooling, the potential utility of and market for the company's and Global Cooling's products and services, [guidance for financial results for 2021 and 2022, including regarding Global Cooling's revenue,] and potential revenue growth and market expansion, including with consideration to our acquisition of Global Cooling, [its 2019 and 2020 acquisitions and giving effect to the COVID-19 pandemic, the company's anticipated future growth strategy, including the acquisition of synergistic cell and gene therapy manufacturing tools and services or technologies, the potential utility of and market for our products and services, potential revenue growth and market expansion, regulatory approvals and/or commercial manufacturing of our customers' products, and potential customer revenue]. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including among other things, uncertainty regarding the satisfaction or waiver of all closing conditions to the acquisition of Global Cooling, the risk that the acquisition may not be completed on the terms or in the time frame expected by the company, unexpected costs, charges or expenses resulting from the acquisition of Global Cooling unexpected costs, charges or expenses resulting (or from the company’s 2019 and 2020 acquisitions), market adoption of the company’s products (including the company’s recently acquired products and the products of Global Cooling, if acquired); the ability of the Global Cooling acquisition (or the company’s 2019 and 2020 acquisitions) to be accretive on the company’s financial results; the ability of the company to continue to implement its business strategy; uncertainty regarding third-party market projections; market volatility; competition; litigation; the impact of the COVID-19 pandemic; and those other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

 

Non-GAAP Measures of Financial Performance:

 

To supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measures of financial performance are included in this release: adjusted gross profit and gross margin, adjusted operating expenses, adjusted operating income/(loss), adjusted net income/(loss), adjusted earnings per diluted share (EPS), earnings before interest, taxes, depreciation and amortization (EBITDA), and adjusted EBITDA. A reconciliation of GAAP to adjusted non-GAAP financial measures is included as an attachment to this press release. When analyzing the Company's operating results, investors should not consider non-GAAP measures as substitutes for the comparable financial measures prepared in accordance with GAAP.

     

Media & Investor Relations

    

Roderick de Greef

Chief Financial and Chief Operating Officer

    

(425) 686-6002

    

rdegreef@biolifesolutions.com

    

 

Page 6 of 11
 

 

BIOLIFE SOLUTIONS, INC.

Unaudited Condensed Statements of Operations

(In thousands, except per share amounts)

 

   

Three Months Ended

    

Year Ended

  
   

December 31,

2020

    

December 31,

2019

    

December 31,

2020

    

December 31,

2019

  

Product revenue

   $ 12,520     $ 7,951     $ 44,540     $ 26,844  

Rental revenue

     454       344       1,795       527  

Service revenue

     1,752       -       1,752       -  

Total revenue

     14,726       8,295       48,087       27,371  

Operating expenses

                                

Cost of product, rental, and service revenue (exclusive of intangible assets amortization)

     6,753       3,050       20,646       8,760  

Research and development

     1,854       1,087       6,720       3,168  

Sales and marketing

     1,883       1,669       6,413       4,701  

General and administrative

     4,684       2,186       14,607       8,893  

Intangible assets amortization

     933       614       3,033       1,079  

Acquisition costs

     251       402       668       940  

Change in fair value of contingent consideration

     3,103       50       1,575       50  

Total operating expenses

     19,461       9,058       53,662       27,591  

Operating income

     (4,735 )     (763 )     (5,575 )     (220 )
                                 

Other income (expense), net

                                

Change in fair value of warrant liability

     (866 )     2,115       3,601       (12,835 )

Change in fair value of investments

     209       -       1,319       -  

Gain on acquisition of SAVSU

     -       -       -       10,108  

Other income/(loss)

     (1 )     90       58       (251 )

Total other income (expenses), net

     (658 )     2,205       4,978       (2,978 )
                                 

Net income before income taxes

     (5,393 )     1,442       (597 )     (3,198 )

Income tax benefit

     (3,264 )     (1,541 )     (3,264 )     (1,541 )

Net income (loss)

   $ (2,129 )   $ 2,983     $ 2,667     $ (1,657 )
                                 

Earnings (loss) per share attributable to common stockholders:

                                

Basic

   $ (0.06 )   $ 0.12     $ 0.09     $ (0.09 )

Diluted

   $ (0.06 )   $ 0.03     $ (0.03 )   $ (0.09 )

Weighted average shares used to compute earnings per share attributable to common stockholders:

                                

Basic

     32,960,437       20,613,360       27,306,258       19,460,299  

Diluted

     32,960,437       25,797,286       27,306,258       19,460,299  

 

Page 7 of 11
 

 

BIOLIFE SOLUTIONS, INC.

CONDENSED BALANCE SHEET INFORMATION

(Unaudited, amounts in thousands)

 

   

Year Ended

  
   

December 31,

2020

    

December 31,

2019

  

Cash, cash equivalents and restricted cash

   $ 90,456     $ 6,448  

Accounts receivable, net

     8,006       5,345  

Inventories

     11,602       10,972  

Total current assets

     114,712       24,113  

Total assets

     234,829       92,816  
                 

Accounts payable

     3,672       3,119  

Total current liabilities

     15,573       7,669  

Total liabilities

     29,583       49,362  

Total Shareholders' equity

   $ 205,246     $ 43,454  

 

 

BIOLIFE SOLUTIONS, INC.

CONDENSED STATEMENT OF CASH FLOWS INFORMATION

(Unaudited, amounts in thousands)

 

   

Year Ended

  
   

December 31,

2020

    

December 31,

2019

  

Cash provided by operating activities

   $ 6,515     $ 1,213  

Cash used in investing activities

     (23,731 )     (27,018 )

Cash provided by financing activities

     101,224       1,596  

Net increase (decrease) in cash, cash equivalents and restricted cash

   $ 84,008     $ (24,209 )

 

 

BIOLIFE SOLUTIONS, INC.

RECONCILIATION OF GAAP GROSS PROFIT TO NON-GAAP (ADJUSTED) GROSS PROFIT

(Unaudited, amounts in thousands)

 

   

Three Months Ended

    

Year Ended

  
   

December 31,

2020

    

December 31,

2019

    

December 31,

2020

    

December 31,

2019

  

GAAP GROSS PROFIT

   $ 7,387     $ 4,732     $ 25,113     $ 17,706  

GAAP GROSS MARGIN

     50

%

     57

%

     52

%

     65

%
                                 

ADJUSTMENTS TO GROSS PROFIT:

                                

Inventory step-up charges

     21       134       411       289  

Intangible assets amortization

     586       513       2,328       905  

ADJUSTED GROSS PROFIT

   $ 7,994     $ 5,379     $ 27,852     $ 18,900  

ADJUSTED GROSS MARGIN

     54

%

     65

%

     58

%

     69

%

 

Page 8 of 11
 

 

BIOLIFE SOLUTIONS, INC.

RECONCILIATION OF GAAP OPERATING EXPENSES TO NON-GAAP (ADJUSTED) OPERATING EXPENSES

(Unaudited, amounts in thousands)

 

   

Three Months Ended

    

Year Ended

  
   

December 31,

2020

    

December 31,

2019

    

December 31,

2020

    

December 31,

2019

  

GAAP OPERATING EXPENSES

   $ 19,461     $ 9,058     $ 53,662     $ 27,591  
                                 

ADJUSTMENTS TO OPERATING EXPENSES:

                                

Cost of product, rental, and service revenue

     (6,753 )     (3,050 )     (20,646 )     (8,760 )

Acquisition and integration costs

     (251 )     (402 )     (668 )     (940 )

Intangible assets amortization

     (933 )     (614 )     (3,033 )     (1,079 )

Loss on disposal of assets

     (172 )     -       (181 )     -  

Change in fair value of contingent consideration

     (3,103 )     (50 )     (1,575 )     (50 )

ADJUSTED OPERATING EXPENSES

   $ 8,249     $ 4,942     $ 27,559     $ 16,762  

 

 

BIOLIFE SOLUTIONS, INC.

RECONCILIATION OF GAAP OPERATING INCOME TO NON-GAAP (ADJUSTED) OPERATING INCOME

(Unaudited, amounts in thousands)

 

   

Three Months Ended

    

Year Ended

  
   

December 31,

2020

    

December 31,

2019

    

December 31,

2020

    

December 31,

2019

  

GAAP OPERATING INCOME

   $ (4,735 )   $ (763 )   $ (5,575 )   $ (220 )
                                 

ADJUSTMENTS TO OPERATING INCOME:

                                

Inventory step-up charges

     21       134       411       289  

Acquisition and integration costs

     251       402       668       940  

Intangible assets amortization

     933       614       3,033       1,079  

Loss on disposal of assets

     172       -       181       -  

Change in fair value of contingent consideration

     3,103       50       1,575       50  

ADJUSTED OPERATING INCOME/(LOSS)

   $ (255 )   $ 437     $ 293     $ 2,138  

 

Page 9 of 11
 

 

BIOLIFE SOLUTIONS, INC.

RECONCILIATION OF GAAP NET INCOME TO NON-GAAP (ADJUSTED) NET INCOME

(Unaudited, amounts in thousands)

 

   

Three Months Ended

    

Year Ended

  
   

December 31,

2020

    

December 31,

2019

    

December 31,

2020

    

December 31,

2019

  

GAAP NET INCOME/(LOSS)

   $ (2,129 )   $ 2,983     $ 2,667     $ (1,657 )
                                 

ADJUSTMENTS TO NET INCOME/(LOSS):

                                

Inventory step-up charges

     21       134       411       289  

Acquisition and integration costs

     251       402       668       940  

Intangible assets amortization

     933       614       3,033       1,079  

Loss on disposal of assets

     172       -       181       13  

Loss on Equity Method Investment

     -       -       -       739  

Gain on acquisition

     -       -       -       (10,108 )

Change in fair value of contingent consideration

     3,103       50       1,575       50  

Change in fair value of investments

     (209 )     -       (1,319 )     -  

Change in fair value of warrant liability

     866       (2,115 )     (3,601 )     12,835  

Income tax benefit

     (3,264 )     (1,541 )     (3,264 )     (1,541 )

ADJUSTED NET INCOME/(LOSS)

   $ (256 )   $ 527     $ 351     $ 2,639  

 

 

BIOLIFE SOLUTIONS, INC.

RECONCILIATION OF GAAP NET INCOME PER DILUTED SHARE TO NON-GAAP (ADJUSTED) NET INCOME PER DILUTED SHARE

(Unaudited, amounts in thousands)

 

   

Three Months Ended

    

Year Ended

  
   

December 31,

2020

    

December 31,

2019

    

December 31,

2020

    

December 31,

2019

  

GAAP NET INCOME/(LOSS) PER SHARE - DILUTED

   $ (0.06 )   $ 0.03     $ (0.03 )   $ (0.09 )
                                 

ADJUSTMENTS TO NET INCOME/(LOSS) PER SHARE – DILUTED:

                                

Inventory step-up charges

     -       0.01       0.02       0.01  

Acquisition and integration costs

     0.01       0.02       0.02       0.05  

Intangible assets amortization

     0.03       0.02       0.11       0.06  

Loss on Equity Method Investment

     -       -       -       0.04  

Gain on acquisition

     -       -       -       (0.52 )

Change in fair value of contingent consideration

     0.09       -       0.06       -  

Change in fair value of investments

     (0.01 )     -       (0.05 )     -  

Change in fair value of warrant liability

     0.03       -       -       0.66  

Income tax benefit

     (0.10 )     (0.06 )     (0.12 )     (0.08 )

ADJUSTED NET INCOME/(LOSS) PER SHARE - DILUTED

   $ (0.01 )   $ 0.02     $ 0.01     $ 0.13  

 

Page 10 of 11
 

 

BIOLIFE SOLUTIONS, INC.

RECONCILIATION OF GAAP NET INCOME TO NON-GAAP (ADJUSTED) EBITDA

(Unaudited, amounts in thousands)

 

   

Three Months Ended

     Year Ended  
   

December 31,

2020

    

December 31,

2019

    

December 31,

2020

    

December 31,

2019

  

GAAP NET INCOME/(LOSS)

   $ (2,129 )   $ 2,983     $ 2,667     $ (1,657 )
                                 

ADJUSTMENTS:

                                

Interest expense/(income), net

     -       (89 )     (58 )     (501 )

Income tax benefit

     (3,264 )     (1,541 )     (3,264 )     (1,541 )

Depreciation

     581       344       2,035       718  

Intangible assets amortization

     933       614       3,033       1,078  

EBITDA

   $ (3,879 )   $ 2,311     $ 4,413     $ (1,903 )
                                 

OTHER ADJUSTMENTS:

                                

Share-based compensation (non-cash)

     2,164       883       5,981       3,043  

Acquisition and integration costs

     251       402       668       940  

Inventory step-up charges

     21       134       411       289  

Loss on disposal of assets

     172       -       180       13  

Loss from equity-method investment (SAVSU)

     -       -       -       739  

Gain on acquisition

     -       -       -       (10,108 )

Change in fair value of contingent consideration

     3,103       50       1,575       50  

Change in fair value of investments

     (209 )     -       (1,319 )     -  

Change in fair value of warrant liability

     866       (2,115 )     (3,601 )     12,835  

ADJUSTED EBITDA

   $ 2,489     $ 1,665     $ 8,308     $ 5,898  

 

 

# # #

 

Page 11 of 11
 EX-99.2 3 ex_235926.htm EXHIBIT 99.2 ex_235926.htm

Exhibit 99.2

 

 biolife.jpg

 

BioLife Solutions to Acquire Stirling Ultracold in an All-Stock Merger

 

Including Stirling, BioLife’s Q4 2020 Annualized Revenue Totals $115 Million

 

Mid to Long Term Adjusted EBITDA Margin Target of 30%

 

Stirling CEO Dusty Tenney to Join BioLife as President & COO

 

Conference Call Begins at 4:30 p.m. Eastern Time Today

 

BOTHELL, Wash. (March 22, 2021) – BioLife Solutions, Inc. (NASDAQ: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced the signing of a definitive merger agreement to acquire Global Cooling, Inc., operating as Stirling Ultracold (“Stirling”), a privately held manufacturer of ultra-low temperature (“ULT”) mechanical freezers.

 

BioLife will issue 6,646,870 shares of common stock for 100% of the outstanding shares of Stirling in an all-stock transaction, which is expected to close early in the second quarter of 2021. With Stirling, BioLife believes that total GAAP revenue in 2021 will exceed $100 million and the transaction is expected to be accretive on an adjusted Net Income per share basis (Non-GAAP) in 2022 and beyond.

 

BioLife also announced 2020 revenue of $48.1 million, a 76% increase over 2019, driven by a 32% increase in biopreservation media revenue, combined with the impact of the results of the Company’s prior acquisitions. Stirling’s preliminary, unaudited, 2020 revenue was $39 million.

 

Mike Rice, BioLife Solutions CEO, remarked, “With this transaction, we continue to execute our M&A strategy to consolidate the bioproduction tools and services space by adding novel and disruptive technologies to our portfolio. This acquisition superbly complements our offering. Combining Stirling’s -20°C to -86°C freezer systems with our current liquid nitrogen (“LN2”) freezers provides complete ULT coverage of cold-chain infrastructure critical for personalized medicine. Further, Stirling’s intellectual property portfolio of 80 patents fulfills our goal of acquiring novel and disruptive technologies that we can market to our cell and gene therapy customers, as well as to the broader biopharma industry. Demand for Stirling’s ULT freezers is significant, fueled by the storage requirements for COVID-19 vaccines. Our longer-term outlook for Stirling is bullish as the total addressable market for ULT freezers in the U.S. alone is estimated to reach nearly $800 million by 2027.”1

 

Rice continued, “In conjunction with this transaction, Stirling CEO, Dusty Tenney, will join BioLife as president and chief operating officer. Dusty brings a stellar track record of executing scale-up initiatives in the life sciences industry to drive growth, having previously overseen an increase in annual revenue from $65 million to $330 million in five years as president of the life sciences division of Brooks Automation. We are delighted to welcome Dusty and the entire Stirling team to BioLife.”

 

1 Ultra-low Temperature Freezer Market Size, Share & COVID-19 Impact Analysis, By Type (Chest and Upright), By Capacity (Less than 300 Liters, 301-500 Liters, 501-700 Liters, 701-900 Liters and More than 900 Liters), By Application (Bio Banks & Hospitals, Academic & Research Laboratories and Others) and Regional Forecast, 2020-2027.

https://www.fortunebusinessinsights.com/ultra-low-temperature-freezer-market-104479

 

 
 

 

Dusty Tenney, CEO of Stirling Ultracold, commented, “BioLife Solutions has assembled an impressive, integrated suite of consumables, equipment, biorepositories, informatics and services to address the growing cell and gene therapy space. As such, Stirling shareholders and our 150 employees will immediately benefit from the breadth and scale of technologies and customers as part of BioLife. Mike Rice and the senior leadership at BioLife have established a well-run company underpinned by an extraordinary company culture that supports both business and personal growth. I’m looking forward to the close of this merger and joining BioLife as president and COO and contributing to the continued success of the company.”

 

Benefits of the Transaction

 

Entry into the high-growth ULT -20°C to -86°C freezer market

 

●

Stirling is uniquely positioned with a portfolio of mechanical freezers utilizing the proprietary Stirling engine, that completely spans the non-liquid nitrogen storage temperature range for frozen biologics, including vaccines. Combined with BioLife’s current Custom Biogenic Systems (“CBS”) LN2 freezers, we can now offer customers the broadest portfolio of freezers for temperature-sensitive materials.
 

●

Stirling has partnered with UPS and other logistics providers to supply ULT freezers and accessories for distribution and point of care storage of COVID-19 vaccines.

 

Cross-selling opportunities

 

●

BioLife intends to fully leverage its extensive relationships with leading cell and gene therapy companies to drive sales of Stirling freezers. 
 

●

BioLife also envisions opportunities to market to Stirling’s customers by offering BioLife's full portfolio of bioproduction tools and services including CryoStor® and HypoThermosol® biopreservation media, ThawSTAR® automated thawing products, the evo® cold chain management system, CBS LN2 freezers and SciSafe biologic storage services.

 

Vertical integration synergies 

 

●

Lower capital costs by deploying Stirling freezers in SciSafe global biorepositories.
 

●

Potential to expand manufacturing capacity for Stirling freezers at BioLife’s CBS facilities.
 

●

BioLife will expand the reach of the Stirling sales team and distributors to provide access to the entire BioLife bioproduction tools and services portfolio offered to the cell and gene therapy and biopharma markets.

 

Financial Impact of the Stirling Acquisition

 

BioLife expects the acquisition of Stirling to impact the Company's financial performance as follows:

 

●

2021 revenue contribution is expected to be approximately $35 – $37 million depending on the actual closing date of the transaction, which is currently expected to occur on or before May 1.
 

●

Stirling’s historical gross margins are in the low 30% range. Identified margin expansion opportunities are expected to drive Stirling’s gross margins into the mid to high 40% range in the mid-term.
 

●

The transaction is expected to be accretive on an adjusted Net Income per share basis (Non-GAAP) in 2022 and beyond.

 

 
 

 

Roderick de Greef, BioLife’s chief financial and operating officer, remarked, “The combined companies annualized revenue run rate is approximately $115 million, based on our revenue in the fourth quarter of 2020 of $14.7 million, and Stirling’s unaudited revenue for the fourth quarter of 2020 of $14 million, While we expect to see some near-term margin dilution as a result of the transaction, however, we anticipate the combined entity will achieve our targeted adjusted EBITDA margin range of 30% in the mid to longer term.”

 

Following the close of this transaction, BioLife intends to keep the Stirling Ultracold brand and to maintain its existing staff and facilities in Athens, Ohio.

 

Conference Call & Webcast

 

BioLife and Stirling management will host a conference call to discuss this announcement and answer questions at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) today.

 

To access the webcast, log onto the Investor Relations page of the BioLife Solutions website at http://www.biolifesolutions.com/earnings. Alternatively, you may access the live conference call by dialing 1 (844) 825-0512 or international callers 1 (315) 625-6880 with the following Conference ID: 7158827. A webcast replay will be available approximately two hours after the call and will be archived on http://www.biolifesolutions.com/ for 90 days.

 

About Stirling Ultracold

 

Stirling Ultracold, a division of Global Cooling, Inc., manufactures and sells environmentally sustainable ultra-low temperature (ULT) freezers for the global market from its headquarters in Athens, Ohio. Powered by the free-piston Stirling engine, and the first in the U.S. to use 100 percent natural refrigerants, these upright and undercounter ULT freezers use less than one-third the electric power of standard compressor-based ULT freezers, as validated by the industry’s first ENERGY STAR® partnership for ULT freezers. The company also produces the industry’s only portable ULT solution available for remote clinical trials and biologic drug delivery. For more information, please call (740) 274-7900, or visit the company’s website, www.StirlingUltracold.com.

 

About BioLife Solutions

 

BioLife Solutions is a leading supplier of class-defining cell and gene therapy bioproduction tools and services. Our tools portfolio includes our proprietary CryoStor® freeze media and HypoThermosol® shipping and storage media, ThawSTAR® family of automated, water-free thawing products, evo® cold chain management system, Custom Biogenic Systems high capacity storage freezers and SciSafe biologic storage services. For more information, please visit www.biolifesolutions.com, and follow BioLife on Twitter.

 

 
 

 

Cautions Regarding Forward-Looking Statements

 

Except for historical information contained herein, this presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements concerning the expected financial performance of the company following the completion of its 2019 and 2020 acquisitions and giving effect to the COVID-19 pandemic, the company's ability to implement its business strategy and anticipated business and operations, in particular following the closing of its acquisition of Global Cooling, the expected synergies between the company and Global Cooling, the company’s ability to realize all or any of the anticipated benefits associated with the acquisition of Global Cooling, the company's ability to implement its business strategy and anticipated business and operations, including following the acquisition of Global Cooling, the potential utility of and market for the company's and Global Cooling's products and services, guidance for financial results for 2021 and 2022, including regarding Global Cooling's revenue, and potential revenue growth and market expansion, including with consideration to our acquisition of Global Cooling, its 2019 and 2020 acquisitions and giving effect to the COVID-19 pandemic, the company's anticipated future growth strategy, including the acquisition of synergistic cell and gene therapy manufacturing tools and services or technologies, the potential utility of and market for our products and services, potential revenue growth and market expansion, regulatory approvals and/or commercial manufacturing of our customers' products, and potential customer revenue. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including among other things, uncertainty regarding the satisfaction or waiver of all closing conditions to the acquisition of Global Cooling, the risk that the acquisition may not be completed on the terms or in the time frame expected by the company, unexpected costs, charges or expenses resulting from the acquisition of Global Cooling unexpected costs, charges or expenses resulting (or from the company’s 2019 and 2020 acquisitions), market adoption of the company’s products (including the company’s recently acquired products and the products of Global Cooling, if acquired); the ability of the Global Cooling acquisition (or the company’s 2019 and 2020 acquisitions) to be accretive on the company’s financial results; the ability of the company to continue to implement its business strategy; uncertainty regarding third-party market projections; market volatility; competition; litigation; the impact of the COVID-19 pandemic; and those other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

 

Non-GAAP Measures of Financial Performance:

 

To supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following projected non-GAAP measures of financial performance are included in this release: adjusted EBITDA margin which is adjusted EBITDA (defined by GAAP net income/(loss) adjusting for interest expense/(income), income taxes, depreciation, intangible asset amortization, share-based compensation, acquisition costs, inventory step-up charges, loss on disposal of assets, change in fair value of contingent consideration, change in fair value of investments and change in fair value of warrant liability) divided by GAAP revenue; and adjusted Net Income per share which is defined by GAAP Net income/loss per share – diluted adjusted for on a per share basis: inventory step-up charges, acquisition costs, intangible asset amortization, change in fair value of contingent consideration, change in fair value of investments, change in fair value of warrants liability and income tax benefit. When analyzing the Company's operating results, investors should not consider non-GAAP measures as substitutes for the comparable financial measures prepared in accordance with GAAP.

 

 

 

Media & Investor Relations

    

Roderick de Greef

    

Chief Financial Officer & Chief Operating Officer

    

(425) 686-6002

    

rdegreef@biolifesolutions.com

    

 

# # #

 

 
 EX-101.SCH 4 blfs-20210322.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 5 blfs-20210322_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 6 blfs-20210322_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Entity, Emerging Growth Company Title of 12(b) Security Trading Symbol Security Exchange Name Amendment Flag Entity, Central Index Key EX-101.PRE 7 blfs-20210322_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 8 biolife.jpg begin 644 biolife.jpg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end XML 9 bioli20210322_8k_htm.xml IDEA: XBRL DOCUMENT 0000834365 2021-03-22 2021-03-22 false 0000834365 8-K 2021-03-22 BIOLIFE SOLUTIONS, INC. DE 001-36362 94-3076866 3303 Monte Villa Parkway Bothell WA 98021 425 402-1400 false false false false false BioLife Solutions, Inc. Common Shares BLFS NASDAQ XML 10 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Document And Entity Information
Mar. 22, 2021
Document Information [Line Items]  
Entity, Registrant Name BIOLIFE SOLUTIONS, INC.
Document, Type 8-K
Document, Period End Date Mar. 22, 2021
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-36362
Entity, Tax Identification Number 94-3076866
Entity, Address, Address Line One 3303 Monte Villa Parkway
Entity, Address, City or Town Bothell
Entity, Address, State or Province WA
Entity, Address, Postal Zip Code 98021
City Area Code 425
Local Phone Number 402-1400
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity, Emerging Growth Company false
Title of 12(b) Security BioLife Solutions, Inc. Common Shares
Trading Symbol BLFS
Security Exchange Name NASDAQ
Amendment Flag false
Entity, Central Index Key 0000834365

EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 1 96 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.blfs.com/20210322/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports bioli20210322_8k.htm blfs-20210322.xsd blfs-20210322_def.xml blfs-20210322_lab.xml blfs-20210322_pre.xml ex_235925.htm ex_235926.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bioli20210322_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "blfs-20210322_def.xml" ] }, "inline": { "local": [ "bioli20210322_8k.htm" ] }, "labelLink": { "local": [ "blfs-20210322_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "blfs-20210322_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "blfs-20210322.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 26, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "blfs", "nsuri": "http://www.blfs.com/20210322", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bioli20210322_8k.htm", "contextRef": "d20218K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://www.blfs.com/20210322/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bioli20210322_8k.htm", "contextRef": "d20218K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.blfs.com/20210322/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.blfs.com/20210322/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.blfs.com/20210322/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document, Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.blfs.com/20210322/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document, Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.blfs.com/20210322/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity, Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.blfs.com/20210322/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity, Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.blfs.com/20210322/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity, Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.blfs.com/20210322/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity, Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.blfs.com/20210322/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity, Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.blfs.com/20210322/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.blfs.com/20210322/role/statement-document-and-entity-information" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity, Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.blfs.com/20210322/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity, File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.blfs.com/20210322/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity, Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.blfs.com/20210322/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity, Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.blfs.com/20210322/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity, Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.blfs.com/20210322/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.blfs.com/20210322/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.blfs.com/20210322/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.blfs.com/20210322/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.blfs.com/20210322/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.blfs.com/20210322/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.blfs.com/20210322/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.blfs.com/20210322/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.blfs.com/20210322/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.blfs.com/20210322/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 17 0001437749-21-006752-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-21-006752-xbrl.zip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end